An infectious cDNA clone of Vero cell adapted Beaudette strain of IBV was constructed using in vitro assembly of cDNA fragments. The entire genome of IBV was RT-PCR amplified into seven fragments, with each piece overlapping about 10 nucleotides. The fragments were ligated and transcribed to synthesize RNA, which was transfected into BHK-21 cells. These cells were then overlaid onto IBV susceptible Vero cells. After five days transfection, the virus was successfully rescued from the transfected cells. The cDNA clone from our laboratory strain has a five nucleotide insertion not present in the originally sequenced virus, resulting in total genome size of 27,613 nucleotides. The infectious cDNA clone was further manipulated to demonstrate its potential as a gene transfer vector, by replacing the ORF5a open reading frame with enhanced green fluorescent protein. The recombinant infectious cDNA clone was also successfully rescued after three days transfection of BHK-21 cells followed by co-culturing with Vero cells. This study showed that the 5a protein, whose function is not known, is not necessary for in vitro IBV replication. This study also showed that the 5a ORF is a good candidate for an insertion site of recombinant genes for the development of IBV infectious cDNA clone as a gene transfer vector.

An infectious cDNA clone of Vero cell adapted Beaudette strain of IBV was constructed using in vitro assembly of cDNA fragments. The entire genome of IBV was RT-PCR amplified into seven fragments, with each piece overlapping about 10 nucleotides. The fragments were ligated and transcribed to synthesize RNA, which was transfected into BHK-21 cells. These cells were then overlaid onto IBV susceptible Vero cells. After five days transfection, the virus was successfully rescued from the transfected cells. The cDNA clone from our laboratory strain has a five nucleotide insertion not present in the originally sequenced virus, resulting in total genome size of 27,613 nucleotides. The infectious cDNA clone was further manipulated to demonstrate its potential as a gene transfer vector, by replacing the ORF5a open reading frame with enhanced green fluorescent protein. The recombinant infectious cDNA clone was also successfully rescued after three days transfection of BHK-21 cells followed by co-culturing with Vero cells. This study showed that the 5a protein, whose function is not known, is not necessary for in vitro IBV replication. This study also showed that the 5a ORF is a good candidate for an insertion site of recombinant genes for the development of IBV infectious cDNA clone as a gene transfer vector.

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / Porcine reproductive and respiratory syndrome virus (PRRSV) was isolated for the first time in 1991 and since then it has been associated with significant economic losses to the pig industry worldwide. Although vaccination against PRRSV is widely used, an important advance would be the development of marker vaccines allowing serologic discrimination between vaccinated and naturally infected animals. The present study aimed to identify immunogenic and conserved regions dispensable to viral replication in different PRRSV proteins, which could be used as negative serologic markers in a new generation of liveattenuated vaccines. A fine mapping of B-cell linear epitopes in different PRRSV proteins by Pepscan is presented in the first part of this thesis. The results indicated the presence of several B-cell linear epitopes in the non-structural protein 2 (Nsp2) and in all structural proteins encoded by PRRSV, which were consistently recognized by antibodies raised in pigs experimentally infected with a North American strain of the virus (NVSL97-7895). The Nsp2 was found to harbor the highest frequency of immunodominant epitopes (n=18) when compared to structural proteins. In the structural proteins, epitopes consistently recognized by immune sera were located in all studied proteins. Overall, the highest degree of immunogenicity and conservation was exhibited by two epitopes identified in the C-terminal end of the M protein (ORF6). The antibodies recognizing the immunodominant epitopes of each protein were detected as early as days 7 to 15 post-infection (p.i.) and remained detectable until the end of the experiment (day 90 p.i). Based on their immunodominance and level of amino acid (aa) conservation, two target epitopes were selected to serve as serological marker candidates in each of the following PRRSV proteins: Nsp2, GP3 and M. These epitopes were deleted in the wild-type cDNA infectious clone (FL-12) by site-directed mutagenesis. The results of this study are presented in the second part of this thesis. A Nsp2 mutant virus (FLdNsp2/44) was successfully rescued following RNA transfection in MARC 145 cells. This epitope deletion mutant fulfilled the requirements for a differential vaccine virus such as efficient growth in vitro and in vivo and induction of active seroconversion as measured by a commercial ELISA kit associated with the absence of a marker-specific peptide-ELISA response in 100% (n=15) of the vaccinated animals. In vitro and in vivo characterization of the mutant virus clearly showed that removal of a 15-mer Nsp2 epitope had no effect on the immunogenicity, growth properties or virulence when compared to the wild type virus. On the other hand, deletions of previously identified peptide marker candidates within GP3 and M genes were shown to be lethal for virus viability in vitro. Alternatively, by substitution of 5aa at a time within a M peptide marker candidate, a viable mutant virus could be recovered although it still resulted in a positive marker virus. In summary, our results provide proof of concept that PRRSV marker vaccines can be developed using such methodology. Taken together, these data indicate that the combination of a mutant virus carrying a deletion of an immunodominant epitope and the corresponding peptide ELISA represents an attractive approach for the development of PRRSV differential modified-live vaccines. / O vírus da síndrome respiratória e reprodutiva dos suínos (PRRSV) foi isolado pela primeira vez em 1991 e, desde então, tem sido associado a perdas significativas para a suinocultura mundial. Apesar da vacinação contra o PRRSV ser amplamente utilizada, um grande avanço seria alcançado com a elaboração de vacinas diferenciais que permitam a discriminação sorológica entre animais vacinados e naturalmente infectados. O presente estudo teve como objetivo a identificação de regiões imunogênicas, conservadas e dispensáveis a replicação viral, em diferentes proteínas do PRRSV, que pudessem ser utilizadas como marcadores sorológicos negativos em uma nova geração de vacinas atenuadas. Na primeira parte desta tese estão apresentados os resultados de um mapeamento de epítopos lineares de linfócitos B em diferentes proteínas do PRRSV, pelo uso da tecnologia de Pepscan. Os resultados indicam a presença de diversas regiões imunodominantes na proteína não estrutural 2 (Nsp2) e em todas as proteínas estruturais do vírus. Essas regiões foram consistentemente reconhecidas pelo soro de suínos experimentalmente infectados com uma cepa norte-americana do PRRSV (NVSL97-7895). A maior freqüência de epítopos imunodominantes foi identificada na Nsp2 (n=18) e o mais alto grau de imunogenicidade e nível de conservação de aminoácidos foi observado em dois epítopos identificados na extremidade carboxi-terminal da proteína M (ORF6). Anticorpos reagentes com epítopos imunodominantes de cada proteína foram detectados inicialmente entre os dias 7-15 pós-infecção (pi), permanecendo em altos títulos até o final do experimento (dia 90 pi). Com base na imunodominância e nível de conservação de amino ácidos (aa) das seqüências mapeadas, dois epítopos alvos foram selecionados como candidatos a marcadores sorológicos negativos em cada uma das proteínas Nsp2, Gp3 e M. Esses epítopos foram então deletados em um clone infeccioso de cDNA (FL12) por mutagênese sítio-direcionada. Os resultados desses experimentos encontram-se descritos na segunda parte da tese. Um vírus mutante carreando a deleção de um epítopo imunodominante da Nsp2 (FLdNsp2/44) foi obtido após transfeccção de RNA viral em células MARC145. A caracterização in vitro e in vivo do vírus mutante demonstrou que a remoção dos 15 aa da Nsp2 não produziu efeito sobre a imunogenicidade, replicação ou virulência quando comparado ao vírus parental. Além disso, observou-se indução de soroconversão contra o PRRSV em animais infectados, detectada pelo uso de um teste ELISA comercial. Por outro lado, não foi detectada resposta humoral específica contra a região deletada nos animais imunizados com o FLdNsp2/44, conforme resultados de um teste ELISA contendo como antígeno um peptídeo sintético correspondente a seqüência removida. Por outro lado, deleções dos epítopos previamente identificados na Gp3 e proteína M foram letais à viabilidade viral in vitro. Alternativamente, um outro vírus mutante foi gerado pela substituição de 5 aa do epítopo identificado na proteína M, embora a alteração de resíduos não tenha sido suficiente para eliminar a imunogenicidade da região. Em resumo, os resultados do presente estudo se constituem em uma prova de conceito no sentido do desenvolvimento de vacinas diferenciais contra o PRRSV. A utilização de um vírus mutante carreando a deleção de um epítopo imunodominante, associado com um teste de ELISA baseado no peptídeo sintético correspondente a região deletada, representam uma alternativa para o desenvolvimento de vacinas diferenciais atenuadas contra o PRRSV.

Ljungan virus (LV) is a recently identified picornavirus of the genus Parechovirus. LV has been isolated from voles trapped in Sweden and also in the United States. LV infected small rodents may suffer from diabetes type 1 and type 2 like symptoms, myocarditis and encephalitis. LV has been proposed as a human pathogen, with indications of causing diabetes type 1, myocarditis and intrauterine fetal deaths. In this thesis, cell culture adapted LV strains were utilised for development and adaptation of several basic methodological protocols to study the LV biology, e.g. real time PCR, highly specific antibodies and a reverse genetics system. These methods allowed detailed studies of this virus and how it interacts with the host cell. The genomic 5'-end was identified and modelling showed unique secondary structure folding of this region. The LV encodes an aphthovirus-like 2A protein with a DvExNPGP motif. This motif was found to mediate primary cleavage of the LV polyprotein in vitro and is proposed to constitute the carboxy terminus of the structural protein VP1 in LV. Rabbit polyclonal antibodies generated against recombinant structural proteins were used to verify that the LV virion is composed of the structural proteins VP0, VP1 and VP3. Cell culture studies showed that LV replicates to low titer with an absent or delayed cell lysis. LV is proposed to be able to spread by a, for picornaviruses, not previously demonstrated direct cell-to-cell transmission. All results taken together suggest a maintenance strategy of LV including low amounts of the LV genome and persistently infected hosts. Stability studies showed that the LV virion not only maintain activity in acidic and alkaline environments but also exhibit resistance to the commonly used disinfectant Virkon®.The results presented in this thesis show that LV has several unique properties, not previously observed for a picornavirus.